ASTRO 2020 virtual meeting

Abstract

George Shenouda (McGill University, Montreal, QC, Canada) presented a phase 2 trial of neoadjuvant metformin and temozolomide followed by hypofractionated accelerated radiotherapy with concomitant and adjuvant metformin and temozolomide in 33 patients with glioblastoma. At a median follow-up of 25·1 months, median overall survival was 31·8 months (95% CI 12–59) and median progression-free survival was 15·5 months (10–36). Median overall survival in the 12 patients with methylated MGMT was 45·3 months versus 19·3 months in the 21 patients with unmethylated MGMT—an encouraging result for this subgroup. No unexpected severe adverse events were reported.